Right From The Start: Successfully Managing The Life Cycles Of Cell And Gene Therapies

By Mike Paglia, Chief Operating Officer, ElevateBio BaseCamp

The development of cell and gene therapies (CGTs) is highly complex and challenging. Incredible strides have been made in this area of the biotech industry – including the first wave of products reaching commercialization – but the field is still maturing, leaving gaps in widespread experience and expertise for managing the entire life cycle of CGT product development.

CGT life cycle management involves complex supply chains, traceability systems and analytics to guarantee safety, and navigating the CGT regulatory environment. The cost of failure is considerably high for these products, not only in terms of additional expenditures and delays, but also when it comes to reaching patients in need of life-saving therapies. Correctly managing the life cycle of a CGT product the first time around is paramount. Learn more about the right processes to utilize across the life cycle and why having the right people to develop and execute those processes can ensure success.